Literature DB >> 19816882

Increased free fetal DNA levels in early pregnancy plasma of women who subsequently develop preeclampsia and intrauterine growth restriction.

S Illanes1, M Parra, R Serra, K Pino, H Figueroa-Diesel, C Romero, J A Arraztoa, L Michea, P W Soothill.   

Abstract

OBJECTIVE: To determine if maternal plasma ffDNA is increased early in pregnancies which subsequently develop preeclampsia (PE) and intrauterine growth restriction (IUGR).
METHODS: Blood was obtained at 11-14 weeks and plasma stored. Among those who delivered a male infant and had a birth weight under the tenth centile and/or PE, we divided them into those who delivered before 35 weeks (9) and those who delivered after this gestation (15). A third group with uncomplicated pregnancies was used as controls (24). Real time-polymerase chain reaction (RT-PCR) was carried out to detect the multi-copy Y chromosome associated DSY14 gene.
RESULTS: There were no differences between the ffDNA levels in the group delivered after 35 weeks and the control group (2.23ge/mL-1.61ge/mL p = 0.39). However, the levels of ffDNA at 11-14 weeks were statistically, significantly higher in patients that delivered before 35 weeks (4.34ge/mL-1.61ge/mL p = 0.0018). A logistic regression analysis shows that for every unit (1ge/mL) in which ffDNA increases, the likelihood of having PE or a fetus growing under the tenth centile delivered before 35 weeks increases by 1.67 times (CI 1.13-2.47).
CONCLUSION: The concentration of ffDNA is significantly higher even during early pregnancy, in patients who subsequently develop PE and/or IUGR and are delivered before 35 weeks.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19816882     DOI: 10.1002/pd.2372

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  8 in total

Review 1.  Extracellular nucleic acids in maternal circulation as potential biomarkers for placental insufficiency.

Authors:  Ilona Hromadnikova
Journal:  DNA Cell Biol       Date:  2012-02-24       Impact factor: 3.311

2.  Cell-Free Total and Fetal DNA in First Trimester Maternal Serum and Subsequent Development of Preeclampsia.

Authors:  Robert M Silver; Leslie Myatt; John C Hauth; Kenneth J Leveno; Alan M Peaceman; Susan M Ramin; Philip Samuels; George Saade; Yoram Sorokin; Rebecca G Clifton; Uma M Reddy
Journal:  Am J Perinatol       Date:  2016-07-11       Impact factor: 1.862

3.  Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Zeynep Alpay Savasan; Juan Pedro Kusanovic; Giovanna Ogge; Eleazar Soto; Zhong Dong; Adi Tarca; Bhatti Gaurav; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2011-08-09

Review 4.  Cell-Free Fetal DNA for the Prediction of Pre-Eclampsia at the First and Second Trimesters: A Systematic Review and Meta-Analysis.

Authors:  Elena Contro; Dalila Bernabini; Antonio Farina
Journal:  Mol Diagn Ther       Date:  2017-04       Impact factor: 4.074

5.  Cell-Free DNA (cfDNA) Fetal Fraction in Early- and Late-Onset Fetal Growth Restriction.

Authors:  Danila Morano; Stefania Rossi; Cristina Lapucci; Maria Carla Pittalis; Antonio Farina
Journal:  Mol Diagn Ther       Date:  2018-10       Impact factor: 4.074

6.  Evidence for a role for the adaptive immune response in human term parturition.

Authors:  Nardhy Gomez-Lopez; Rodrigo Vega-Sanchez; Marisol Castillo-Castrejon; Roberto Romero; Karen Cubeiro-Arreola; Felipe Vadillo-Ortega
Journal:  Am J Reprod Immunol       Date:  2013-01-24       Impact factor: 3.886

7.  Quantification and Application of Potential Epigenetic Markers in Maternal Plasma of Pregnancies with Hypertensive Disorders.

Authors:  Hyun Jin Kim; Shin Young Kim; Ji Hyae Lim; Dong Wook Kwak; So Yeon Park; Hyun Mee Ryu
Journal:  Int J Mol Sci       Date:  2015-12-15       Impact factor: 5.923

8.  Usefulness and reliability of cell free fetal DNA screening for main trisomies in case of atypical profile on first trimester maternal serum screening.

Authors:  Julie Carrara; Alexandre Vivanti; Jacques C Jani; Adèle Demain; Jean-Marc Costa; Alexandra Benachi
Journal:  J Transl Med       Date:  2019-11-28       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.